Novavax and Serum Institute of India’s NVX-CoV2373 Receives the DCGI's EUA for the Treatment of COVID-19 in Adolescents Aged ≥12 to <18 Years in India
Shots:
- The DCGI has granted EUA for NVX-CoV2373 which was the 1st protein-based vaccine for adolescents aged ≥12 to <18yrs. with COVID-19. The vaccine was manufactured & marketed in India by SII under the brand name Covovax
- The P-II/III study evaluated the safety & immunogenicity of Covovax in 460 adolescents aged ≥12 to <18yrs. which showed that Covovax was well-tolerated with encouraging safety profile & indicated that the therapy was immunogenic in adolescents
- Covovax is currently underway in patients aged ≥7 to <12 & ≥2 to <7yrs. in India. The authorization also highlights results from an ongoing P-III (PREVENT-19) pediatric expansion trial of NVX-CoV2373 in adolescents aged ≥12 to <18yrs. in the US
Ref: PR Newswire | Image: Novavax
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
